- Welcome and overview
- Risk factors and clinical/economic consequences of hyperkalemia
- Treatment options for hyperkalemia
- Strategies for designing safe and effective treatment plans with oral potassium binders
- Question and answer session
Date / Time
Katherine Di Palo, PharmD, FAHA, FHFSA, BCACP, BCGP
Clinical Program Manager
Hospital Readmissions Reduction Program
Montefiore Medical Center
Assistant Professor of Medicine
Albert Einstein College of Medicine
Michelle Richardson, PharmD, BCPS
Tufts University School of Medicine
Special and Scientific Staff
William B Schwartz Division of Nephrology
Tufts Medical Center
Hyperkalemia is a serious metabolic condition and can lead to life-threatening cardiac arrhythmias and sudden death. This program will provide expert-led guidance to navigate the treatment landscape and to aid the development of optimized treatment plans (integrating the latest research results) for each patient at risk for and with hyperkalemia.
The goal of this activity is to improve the knowledge and competence of learners about the causes, risk factors, and clinical complications of hyperkalemia, novel treatment options for hyperkalemia, and the necessary information to design safe and effective treatment plans for patients with hyperkalemia.
The target audience for this activity is pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with or at risk for hyperkalemia as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.
Upon completion of this activity, participants should be able to:
- Identify causes, risk factors, clinical complications, and economic consequences of hyperkalemia
- Evaluate traditional and novel treatment options for hyperkalemia, including the efficacy and safety of available agents
- Design safe and effective treatment plans for hyperkalemia with an oral potassium binder
ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-22-125-L01-P has been assigned to this live Knowledge-based activity (initial release date 4-12-2022). This activity is approved for 1.5 contact hours (0.15 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. Faculty disclosures will be provided prior to the start of the CE activity.